Mamiko Nishimoto

Linical

Linical Co., Ltd. is a global CRO incepted in 2005. Headquartered in Osaka, Japan, we are dedicated to serve our clients as a true partner. Linical is listed in the prime segment of the Tokyo Stock exchange. With more than 950 employees we directly serve in more than 20 countries in Asia-Pacific including Japan, Europe and North America via our own staff. Linical Europe is headquartered in Germany (Frankfurt) with substantial presence in France (Paris) and Spain (Madrid). Our geographic footprint facilitates a significant presence in the leading Western European markets combined with well-established own operations in key markets in Central and Eastern Europe. • Linical prides itself of a strong track record in all phases of drug development. Our project approach and processes are tailored to meet the specific needs of your trial. Our Medical Affairs Division features access to several full time medics with broad therapeutic experience. • Linical's Corporate Clinical Data Management and Biostatistics team is based in Madrid, Spain, with an additional team located in Seoul, Korea. Our Data Science Center offers tailored concepts across all key therapeutic areas with particular expertise in early phase I/II studies. Moreover, pivotal Phase 2/3 trials are supported, but also late-phase approaches such as observational studies, post approval studies (PAS) and post authorization safety studies (PASS), to serve global as well as regional and national projects. We thrive for efficient solutions that are helping our clients. We work as integrated teams functioning with maximum transparency throughout each study, making sure that the client is kept up to date on progress and all study parameters. Our quality assurance systems supports every aspect of our activities and ensures our deliverables are fully compliant with international and local regulations.